Send to

Choose Destination
Oncotarget. 2018 Nov 16;9(90):36102-36109. doi: 10.18632/oncotarget.26302. eCollection 2018 Nov 16.

Inhibition of breast cancer metastasis to the lungs with UBS109.

Author information

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
Department of Surgery, Emory University, Atlanta, GA 30322, USA.
Department of Pathology, Northwestern University Feinberg School of Medicine and Northwestern Memorial Healthcare, Chicago, IL 60611, USA.
Agilux Laboratories, Inc./Charles River Laboratories, Inc., Worcester, MA 01608, USA.
Emory Institute for Drug Development, Emory University, Atlanta, GA 30322, USA.
Department of Chemistry, Emory University, Atlanta, GA 30322, USA.


Synthetic monocarbonyl analogs of curcumin (MACs) are cytotoxic against several cancers including head and neck cancer, pancreatic cancer, colon cancer, and breast cancer. Mechanisms of action include depolarization of the mitochondrial membrane potential and inhibition of NF-κB, leading to apoptosis. We previously demonstrated that UBS109 (MAC), has preventive effects on bone loss induced by breast cancer cell lines. We determined whether UBS109 could inhibit and prevent lung metastasis, since lung metastasis of breast cancer is a major problem in addition to bone metastasis. A breast cancer lung metastasis (colonization) model was created by injection of breast cancer cells MDA-MB-231 into the tail vein of athymic nude mice, nu/nu. Animals were treated with vehicle or UBS109 at 5 or 15 mg/kg body weight by intraperitoneal injection once daily 5 days a week for 5 weeks. UBS109 at 15 mg/kg significantly inhibited lung metastasis/colonization as demonstrated by reduced lung weight consisting of tumor nodules. The body weight of animals treated with UBS109 15 mg/kg remained the same as in the other groups. UBS109 killed completely (100%) MDA-MB-231 breast cancer cells at 1.25 μM in a cytotoxicity assay in vitro. UBS109 15 mg/kg i.p. showed a maximal blood concentration (Cmax) of 432 ± 387 ng/mL at 15 min post injection. This is approximately 1.5 ng/ml in the blood of mice and equals 1.5 μM of UBS109. These in vitro and in vivo results are consistent with each other.


MACs; UBS109; bone metastasis; breast cancer; lung metastases

Conflict of interest statement

CONFLICTS OF INTEREST The author(s) confirm that this article content has no conflicts of interest.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center